Pfizer: Improving the Pace of Innovation
The extraordinary speed of the 269-day Pfizer-BioNTech COVID-19 vaccine development was the most prominent example of how clinical trials can move quickly while maintaining focus on quality and safety.
Pfizer Supports Affordable Access Through Biosimilars
As patents for biologics expire, biosimilars may provide the same benefits to patients at lower cost.
Pfizer’s Streak of Returning Cash to Shareholders
Pfizer’s most recent quarterly dividend was its 331st in a row. The streak stretches back more than 80 years, spanning major innovation milestones and advances in healthcare.
Pfizer’s Next Potential Breakthrough Vaccine Could Target The Flu
Given the importance of an effective flu vaccine, researchers are in hot pursuit of a new kind of shot.